The Direct Economic Burden of Gout in an Elderly Canadian Population.
To estimate the direct healthcare cost and resource use from the public payer perspective between patients with incident gout and matched gout-free patients in Ontario.



Patients with incident gout aged ≥ 66 with uninterrupted Ontario Health Insurance Plan (OHIP) coverage in the 1-year baseline period were included in the study. Patients with gout were indexed at first gout diagnosis or prescription over the study period April 1, 2008, to March 31, 2014. Gout-free patients with no gout diagnosis within history were matched (up to 5:1) to each patient with gout. Linked medical records were analyzed until end of study, death, or OHIP ineligibility. Bang and Tsiatis adjusted healthcare costs and resource use were compared using bootstrap p-values and 95% CI.



A total of 29,894 patients with gout and 148,231 gout-free patients were included in the study. Patients were 56% male, had a median Adjusted Clinical Group healthcare resource use band of moderate morbidity, and had a median age of 75-79 years. Baseline comorbidities were similar between groups except for renal disease. Analyzing 5-year total healthcare costs, patients with gout ($44,297) incurred a significantly higher average healthcare cost compared to gout-free patients ($33,965), for an incremental cost of $10,332 (95% CI $9617-$11,039; p < 0.01). Similar trends were observed in all individual healthcare component cost and use metrics.



Following onset of gout, patients in Ontario incur significantly greater healthcare costs and resource use compared to matched gout-free patients. Alternative gout management strategies should be investigated to reduce the incremental burden of gout borne by the Ontario healthcare system.
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada. aren.fischer@ca.imsbrogan.com.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada. aren.fischer@ca.imsbrogan.com.
Aren
A
Fischer
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada.
Michel
M
Cloutier
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada.
Jason
J
Goodfield
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada.
Richard
R
Borrelli
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada.
Dawn
D
Marvin
From IMS Health Brogan, and AstraZeneca Canada, Mississauga, Ontario, Canada.|A. Fischer, MSc, IMS Health Brogan; M. Cloutier, PhD, IMS Health Brogan; J. Goodfield, BSc, BA, IMS Health Brogan; R. Borrelli, MBA, IMS Health Brogan; D. Marvin, MSc, AstraZeneca Canada; A. Dziarmaga, PhD, AstraZeneca Canada.
Alison
A
Dziarmaga
D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D003695:Delivery of Health Care / Q000191:economics*; D019468:Disease Management; D005260:Female; D006073:Gout / Q000191:economics* / Q000453:epidemiology; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics; D006801:Humans; D015994:Incidence; D008297:Male; D009864:Ontario / Q000453:epidemiology
AGING; CASE-CONTROL STUDIES; EPIDEMIOLOGY; GOUT; HEALTHCARE COSTS; RETROSPECTIVE STUDIES